Interim Consolidated Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2020

Interim Consolidated Financial Information (Unaudited)

Interim Consolidated Financial Information (Unaudited)

Note 18. Interim Consolidated Financial Information (Unaudited)


	Fiscal 2020 Quarter Ended
(in thousands, except per share data)	March 31,		June 30,		September 30,		December 31,
Revenues⁽¹⁾	$	568,507	$	688,043	$	620,643	$	789,509
Net income (loss)	$	(720,642)	$	290,298	$	(15,203)	$	149,850
Basic net income (loss) per share	$	(3.33)	$	1.33	$	(0.07)	$	0.68
Diluted net income (loss) per share	$	(3.33)	$	1.32	$	(0.07)	$	0.68
Shares used in computation of basic net income (loss) per share		216,721		217,549		218,784		219,239
Shares used in computation of diluted net income (loss) per share		216,721		220,434		218,784		221,228


	Fiscal 2019 Quarter Ended
(in thousands, except per share data)	March 31,		June 30,		September 30,		December 31,
Revenues⁽²⁾	$	497,857	$	529,932	$	551,581	$	579,389
Net income	$	102,312	$	105,318	$	128,271	$	111,005
Basic net income per share	$	0.48	$	0.49	$	0.60	$	0.51
Diluted net income per share	$	0.47	$	0.48	$	0.59	$	0.51
Shares used in computation of basic net income per share		214,065		214,620		215,199		215,770
Shares used in computation of diluted net income per share		217,061		217,483		217,791		218,542

(1)

The quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 include $486.7 million, $500.3 million, $522.3 million, and $559.5 million, respectively, of product revenues, net, relating to JAKAFI, ICLUSIG and PEMAZYRE. The quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 include $81.8 million, $92.8 million, $98.4 million and $119.9 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States and TABRECTA worldwide. The quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 include $0.0 million, $95.0 million, $0.0 million and $110.0 million, respectively, of milestone and contract revenues relating to the Innovent, Lilly and Novartis agreements.

(2)

The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $396.2 million, $433.9 million, $454.0 million, and $490.8 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $61.6 million, $76.0 million, $80.1 million and $88.6 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In December 2018 and July 2019, we entered into collaborative research and license agreements with Innovent and Zai Lab, respectively. The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $40.0 million,

$20.0 million, $17.5 million and $0.0 million, respectively, of milestone and contract revenues relating to these agreements.